From: Nicky Molloy 
Subject: IUFO: Advanced biochip technology for"sequencing" of genomes
Date: 8 May 2000 02:35:27 -0400
To: IUFO 

->  IUFO  Mailing List

I have 277 posts on the hard stuff waiting to get posted on my list, so if
you are into mind control info there are public archives as a library. Did
so much surfing lately just trying to put all the hair raising stuff in one
place.

http://www.egroups.com/messages/armageddon-or-newage

Big Bro in UK , poss MI6 just deleted these posts plus 2 or 3 others from a
list member's computer today.
http://www.egroups.com/message/armageddon-or-newage/1235?&start=1216
http://www.egroups.com/message/armageddon-or-newage/1236?&start=1216
They left the Pokemon post apparently. hmmm

Nicky @@


-----Subject: Advanced biochip technology for"sequencing" of genomes


News Conference
Motorola, Packard Instrument Co. and Argonne
to develop advanced biochip technology
http://www.anl.gov/OPA/news98/transcript.htm
----------------------------------------------------------------------------
----
http://www.osti.gov/biochip.htm
More here


By: Hon. Federico Pena, Secretary of Energy

Hon. Aleksey Ostrovsky, Science Attache, Embassy of the Russian Federation

Dr. Harvey Drucker, Associate Director, Argonne National Laboratory

Dr. Eli Huberman, Director-CMB, Argonne National Laboratory

Rudyard Istvan, Vice President and Corporate Director of Strategy, Motorola
Inc.

Emery Olcott, Chairman and CEO, Packard BioScience Company

Richard McKernan, President, Packard Instrument Company

Dr. Andrei Mirzabekov, Engelhardt Institute of Molecular Biology

For:Biochip Telephone News Conference

At: U.S. Department of Energy, Motorola, and Packard

Date: 9:00 a.m. EDT, Monday, June 29, 1998

DRUCKER:

Good morning, ladies and gentlemen.

I am Harvey Drucker, associate director of Argonne National Laboratory.

Thank you for joining us this morning.

We have all come together electronically today to discuss a new
public-private partnership involving two scientific research organizations
from two nations with two American high-technology companies. The work that
this partnership is undertaking could mark a new era in health and medicine
... greatly expanding our ability to diagnose genetic diseases such as
cancer and multiple sclerosis.

We also expect additional major benefits in animal and plant biology.

With us this morning to discuss both the work and the expected benefits are
senior officials from the partner organizations:

>From the U.S. Department of Energy, Federico Pena, the Secretary of
Energy....

>From Russia, Aleksey Ostrovsky, Science Attache, Embassy of the Russian
Federation to the United States....

>From Argonne National Laboratory, Dr. Eli Huberman, director of the Argonne
Center for Mechanistic Biology and Biotechnology....

>From Motorola Incorporated, Rudyard Istvan, Vice President and Corporate
Director of Strategy ....

>From Packard ... Emery Olcott, Chairman and CEO of Packard BioScience
Company ... and Richard McKernan, president of Packard Instrument Company
... and ....

And from the Engelhardt Institute of Molecular Biology in Moscow, Dr. Andrei
Mirzabekov, the world-renowned biologist who also heads the joint
Argonne-Engelhardt research team.

After brief statements by those individuals, we will open the line to
reporters' questions.

For your convenience, the full text of these remarks and the full text of
the news release are available via Internet at both the U.S. Department of
Energy "home page" and the Argonne National Laboratory home-page. Those
Internet addresses are:www.doe.gov andwww.anl.gov.

Let us begin this morning with one of Washington's strongest supporters of
scientific research, the Secretary of Energy, Federico Pena.

Mr. Secretary....

PENA:

Thank you very much, Dr. Drucker. Good morning, everybody.

This morning we are combining this country's top talents in science and
technology on a project of profound importance to all Americans.

The 21st Century will be a century of great scientific breakthroughs. And
the partnership we are announcing this morning promises to be another.

At the heart of today's announcement is a remarkably advanced biochip. It is
the biological equivalent of a computer microchip, and it's about the same
size. Essentially, it is a glass slide - much like the ones used with a
standard microscope - but with thousands of three-dimensional gels ... each
one like a microscopic test tube.

This small device offers us the potential to analyze the human genome a
thousand times faster than we can do that today. And therefore it holds much
promise for major advances in health and medicine, solutions to
environmental pollution problems,

and strategies for more bountiful, healthy agricultural harvests.

Let me give you just two quick examples of how this new technology can be
used.

Today when doctors have a patient in the hospital, you need to identify an
infectious agent quickly in order to provide the right treatment. We believe
we will be able to save thousands of lives by being able to identify those
infectious agents much more quickly than we can today.

Another example, and one that has received a lot of attention here in the
United States, is responding to biological agents - whether on the
battlefield or in a city where we might see these. This technology will
allow us to more quickly detect the agent and of course provide the
response.

The Department of Energy stared funding this work as part of our effort in
the Human Genome Project to develop new methods for faster sequencing. It
involved experts in optics, chemistry, biology, and computer science working
the kind of team which typified our National laboratories.

This biochip breakthrough resulted from a research and development
partnership between the public and private sectors. Government and industry
are working together to improve America's quality of life.

Since the start of this Administration, both President Clinton and Vice
President Gore outlined what our science objectives, as a nation, ought to
be. They encouraged the emergence of "creative participation" by industry
and government to address

critical national challenges.

Among those challenges were improving human health, creating breakthrough
technologies that would lead to new industries and high quality jobs,
protecting and restoring the global environment, feeding and providing
energy for a growing population,

and of course improving our quality of life.

President Clinton pledged that the American people, who are the principal
sponsors of public investment in science, would also be the principal
beneficiaries.

The biochip commercialization partnership being signed today is part of this
Administration's continuing fulfillment of the President's pledge.

I want to emphasize that the return on public investment is not limited to
the improvements we anticipate in Americans' quality of life. Except for
rewards to private investors, royalties from a commercial biochip will flow
to the U.S. Department of Energy's Argonne National Laboratory for
scientific and technological research.

This morning, we could very well be witnessing the birth of a new
multi-billion dollar industry that will allow our children and their
children to live in a substantially healthier world.

So congratulations to all of today's participants. I'm very excited to
participate in this with them. we wish them well in years to come.

DRUCKER:

Thank you, Mr. Secretary.

Attending this meeting, as I said, is Dr. Aleksey Ostrovsky, science attache
with the embassy of the Russian Federation in Washington. We would like to
say that we have been very pleased with the beginnings and the continuation
of what is a deep and important relationship between scientists of the
United States and scientists of Russia. We believe that this project is
symbolic of the interactions of scientists of both nations. Here are the
best of both countries - working together, pooling their resources for the
benefit of all humanity.

So we would like to thank our Russian friends. We think this is going to be
a large marker on the way toward scientific cooperation in all fields
between the United States and Russia.

Thank you, Dr. Ostrovsky, for being with us today.

It is now my pleasure to introduce Dr. Eli Huberman, who heads the Argonne
Center for Mechanistic Biology and Biotechnology. The spelling of his name
is ... E-L-I ... H-U-B-E-R-M-A-N.

Dr. Huberman....

HUBERMAN:

Thank you, Harvey, and good morning.

Working with Motorola and Packard, we will now commercialize this biological
advance in a five-year, joint research agreement totaling
19-million-dollars. That, we believe, makes this the largest joint research
agreement in biotechnology ever signed by a U.S. Department of Energy
laboratory.

Packard will provide 9.7-million-dollars, and Motorola will provide
9.3-million-dollars. Argonne and Engelhardt are contributing intellectual
property in the form of 19 inventions relating to the biochip. These 19
inventions, which have been licensed exclusively to Motorola and Packard,
are the result of more than 10-million-dollars in research support since
1994 by the U.S. Department of Energy, the Defense Advanced Research
Projects Agency, the Russian Academy of Sciences, and the Russian Human
Genome Program.

With Motorola and Packard making a commercial biochip widely available for
rapid, economical "sequencing" of genomes, we should see more and better
pharmaceuticals developed more rapidly ... faster, more accurate medical
diagnostics ... a heightened ability to assess and repair environmental
damage ... better, more hardy, and healthier crops ... and significant
reductions in health-care costs for us all.

DRUCKER:

Thank you, Eli.

And now from Motorola Incorporated, that company's Vice President and
Corporate Director of Strategy, Rudyard Istvan. The spelling is ...
R-U-D-Y-A-R-D ... I-S-T-V-A-N....

Mr. Istvan.....

ISTVAN:

Motorola is a world leader in semi-conductor and microchip manufacturing,
instrumentation, data processing and communications. As such, we believe we
are the logical company to - over the next several years - develop and
refine the technology to mass produce biochips. Motorola intends to reduce
their cost, improve their quality, and make them widely available to genetic
researchers in many fields.

This new product will be the biological equivalent of a computer microchip -
except that, instead of performing millions of mathematical operations using
electricity, it will decode thousands of genes in minutes. Once use of the
biochip is widespread, major advances are expected in faster more accurate
medical diagnostics, faster testing of new drugs, and quicker detection and
cleanup of environmental pollution....

DRUCKER:

Thank you.

Now I'm pleased to introduce two top Packard executives ... the chairman and
chief executive officer of Packard BioScience Company, Emery Olcott - that's
E-M-E-R-Y O-L-C-O-T-T - and the president of Packard Instrument Company,
Richard McKernan. The spelling of his last name is ... M-C ... capital
K-E-R-N-A-N.

Mr. Olcott.....

OLCOTT:

Packard BioScience Company - through its analytical division, Packard
Instrument Company - develops innovative, high-quality analytical
instrumentation to further life science and drug discovery research. Over
the past 40 years, Packard has developed a progression of technologies with
the goal of simplifying and miniaturizing assay protocols.

Dick?

McKERNAN:

Thanks, Emery.

The biochip technology we are developing with Argonne and Motorola is a
natural progression in our product evolution in miniaturization. Our role is
to develop the analytical instruments and chemical reagents needed to
process and analyze the biochips. To do this, we've created two
instruments - the BioChip Arrayer and the BioChip Imager. Together, they
constitute a single system for dispensing assays onto the biochips and
analyzing the reactions.

The enabling technology behind the biochip is the Piezoelectric tip system -
an advanced liquid handling robot developed by Packard. With the system, the
BioChip Arrayer delivers tiny droplets of assay fluid - as small as 300
picoliters - to the thousands of individual micro-gels on the chip's surface
quickly and accurately.

It is this technology, coupled with Argonne's innovative micro-gel approach,
that differentiates our biochip from what has formerly been introduced to
the market. The advantage of this technique is that it provides a
three-dimensional platform to perform

the assay tests allowing multiple layers of DNA to be stacked for greater
sensitivity and accuracy. Additionally, with our liquid handling
instruments, researchers will be able to dispense DNA information directly
onto the biochips in their own labs, eliminating the need to provide
proprietary research information to the chip manufacturer. Moreover, a wide
variety of biological targets can be immobilized on the chip, including DNA,
gene fragments, and proteins.

To analyze the thousands of biological reactions on the biochip
simultaneously, we created the BioChip Imager, which is a precise laser
optic imaging device. When imaged, each sample produces a different pattern
to provide answers to questions such as DNA sequence, genetic variation,
gene expression, protein interaction, and immune response.

DRUCKER:

Thank you both.

Now our final speaker. From the Engelhardt Institute of Molecular Biology in
Moscow, Dr. Andrei Mirzabekov. And the spelling is ... A-N-D-R-E-I ...
M-I-R-Z-A-B-E-K-O-V.

Dr. Mirzabekov.....

MIRZABEKOV:

The Engelhardt Institute, the Russian Academy of Sciences, and my colleagues
on the research team are proud to be part of such a important project. And
to now see it move beyond the research laboratory.

Our biochips employ a novel "micro-gel" technology in which as many as
10,000 micro-structures are mounted on a single glass surface about the size
of a microscope slide.

Each micro-gel is like a micro-test tube in which chemical compounds can be
tested against biological targets to provide answers to questions about DNA
sequence, genetic variation, gene expression, protein interaction and immune
response.

In addition to being faster than conventional gene sequencing methods, these
biochips provide a three-dimensional platform that allows greater
sensitivity, accuracy, and versatility in assaying proteins, RNA and DNA.

Therefore, what we have developed is an exceptionally fast biochip. Instead
of slowly reading DNA letter by letter, with this biochip we can rapidly
read words, sentences and sometimes even a whole paragraph at a time. It's
like speed-reading the genetic code with one hundred percent comprehension.

By combining the biochips with robots and computers, we can in a matter of
seconds find one genetic variation among three billion otherwise identical
genes. Conventional methods take days.

We eagerly look forward to the day when Motorola and Packard make our
biochip an inexpensive, standard diagnostic tool worldwide.

When that happens, medical and biological researchers will be able to
identify in minutes mutated genes that could lead to later genetic problems,
such as cancer, multiple sclerosis or Alzheimer's. Widespread use of
biochips will also remove the guesswork from early treatment of many
diseases and conditions. By using less than a drop of fluid, doctors will be
able to make fast, accurate, on-the-spot identification of specific
bacteria, viruses, and other micro-organisms.

-- end --



----------------------------------------------------------------------------
----

[Return to Argonne's home page]




-> To unsubscribe send email to iufo-unsubscribe@topica.com
___________________________________________________________
T O P I C A  The Email You Want. http://www.topica.com/t/16
Newsletters, Tips and Discussions on Your Favorite Topics